Sanofi-Aventis ar putea plati 21,3 mld. $ pe producatorul de medicamente Genzyme
Grupul francez Sanofi-Aventis ar putea fi nevoit sa plateasca 21,3 miliarde de dolari (80 centi pe actiune) pentru preluarea producatorului de medicamente Genzyme, peste suma pe care o planificase initial, considera analistii citati de Bloomberg.
:format(webp):quality(80)/https://www.dailybusiness.ro/wp-content/uploads/2010/08/4c56b8be8f6aa.jpg)
Chris Viehbacher, directorul general al Sanofi, are aprobarea Consiliului de Administratie pentru a oferi un pret maxim de 18,7 miliarde de dolari (70 de dolari pe actiune) si pregateste o scrisoare oficiala catre Genzyme, au declarat surse apropiate situatiei.
Sanofi ar putea face o oferta oficiala catre Genzyme in urmatoarele saptamani, de 70 de dolari pe actiune, insa Genzyme poate solicita 80 dolari, spun analistii. In cazul in care cele doua companii nu ajung la un acord, se poate ajunge la o preluare ostila pentru un pret sub 80 de dolari pe titlu.
Genzyme este cel mai mare producator de medicamente pentru boli genetice rare, iar produsele sale au o probabilitate redusa de a fi concurate de medicamente generice, intrucat sunt dezvoltate din celule vii si nu pe baza de compusi chimici.
:format(webp):quality(80)/https://www.dailybusiness.ro/wp-content/themes/strawberry-daily-202207/assets/images/avatar.png){kind=avatar}
Alte articole
:format(webp):quality(80)/https://www.dailybusiness.ro/wp-content/uploads/2026/02/Ilie-Bolojan-3.jpg)
:format(webp):quality(80)/https://www.dailybusiness.ro/wp-content/uploads/2025/12/Drinking-Water.jpg)
:format(webp):quality(80)/https://www.dailybusiness.ro/wp-content/uploads/2026/02/Ariston.jpg)
:format(webp):quality(80)/https://www.dailybusiness.ro/wp-content/uploads/2026/02/robert-negoita-1.jpg)
:format(webp):quality(80)/https://www.dailybusiness.ro/wp-content/uploads/2026/02/Zelenski.jpg)
:format(webp):quality(80)/https://www.dailybusiness.ro/wp-content/uploads/2026/02/Kaja-Kallas-Consiliul-Afaceri-Externe-Aparare.jpg)
:format(webp):quality(80)/https://www.dailybusiness.ro/wp-content/uploads/2026/02/aquila-foto-flota.jpg)
:format(webp):quality(80)/https://www.dailybusiness.ro/wp-content/uploads/2026/02/Sindicalistii-din-sanatate.jpg)
:format(webp):quality(80)/https://www.dailybusiness.ro/wp-content/uploads/2026/01/Curtea-de-Apel-Bucuresti-1.jpg)
:format(webp):quality(80)/https://www.dailybusiness.ro/wp-content/uploads/2026/01/CCR.jpg)
:format(webp):quality(80)/https://www.dailybusiness.ro/wp-content/uploads/2026/02/tronson-autostrada.jpg)
:format(webp):quality(80)/https://www.dailybusiness.ro/wp-content/uploads/2026/01/Bolojan-Guvernul_romaniei-rectorii.jpg)
:format(webp):quality(80)/https://www.dailybusiness.ro/wp-content/uploads/2025/10/orange-vodafone-1.jpg)
:format(webp):quality(80)/https://www.dailybusiness.ro/wp-content/uploads/2026/02/Donald-Trump.jpg)
:format(webp):quality(80)/https://www.dailybusiness.ro/wp-content/uploads/2026/01/ilie-bolojan-1.webp)
:format(webp):quality(80)/https://www.dailybusiness.ro/wp-content/uploads/2026/01/Florin-Barbu.jpg)
:format(webp):quality(80)/https://www.dailybusiness.ro/wp-content/uploads/2026/02/Echipa-LTSM.jpeg)
:format(webp):quality(80)/https://www.dailybusiness.ro/wp-content/uploads/2025/12/CCR.jpg)
